Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Published byCorey Hunter Modified over 9 years ago

Similar presentations

Presentation on theme: "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,"— Presentation transcript:

1 Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle- Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, and Hartmut Döhner Blood Volume 123(21):3247-3254 May 22, 2014 ©2014 by American Society of Hematology

2 Incidence and distribution of gene mutations, genomic aberrations, and IGHV status for the patients with all markers available (n = 573). Stephan Stilgenbauer et al. Blood 2014;123:3247-3254 ©2014 by American Society of Hematology

3 Kaplan-Meier estimates. Stephan Stilgenbauer et al. Blood 2014;123:3247-3254 ©2014 by American Society of Hematology

Download ppt "Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,"

Similar presentations

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,
Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.

Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.
The genetic basis of myelodysplasia and its clinical relevance

The genetic basis of myelodysplasia and its clinical relevance
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,

Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
Should Chlorambucil Be Used with Obinutuzumab in Untreated CLL? Answer: YES! Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma Translational.

Should Chlorambucil Be Used with Obinutuzumab in Untreated CLL? Answer: YES! Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma Translational.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease by Françoise Bernaudin, Gérard Socie, Mathieu Kuentz,

Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease by Françoise Bernaudin, Gérard Socie, Mathieu Kuentz,
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.

Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
Meeting with Hiren.

Meeting with Hiren.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,
Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene by A.

Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene by A.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No

Can Kinase Inhibitors and Immunomodulators Replace Chemotherapy? No
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders by Konstanze Döhner, Jill.

Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders by Konstanze Döhner, Jill.
Fluorescence in situ hybridization confirms the presence of Merkel cell polyomavirus in chronic lymphocytic leukemia cells by Anke Maria Haugg, Ernst-Jan.

Fluorescence in situ hybridization confirms the presence of Merkel cell polyomavirus in chronic lymphocytic leukemia cells by Anke Maria Haugg, Ernst-Jan.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Similar presentations

Ads by Google